US biotech sector broadly higher, Genmab extends intraday gain to over 25% to record high

Odaily reports: According to MSX.COM data, biotech company Genmab extended its intraday gain to over 25%, with its share price hitting a record high; the company announced the latest data from its Phase III LiGeR-HN1 study of Petosemtamab, showing that the combination therapy reduced the risk of death in patients with head and neck squamous cell carcinoma by 50%.

Among US biotech stocks, Twist Bioscience rose over 9%, Recursion Pharmaceuticals rose over 8%, and Moderna rose over 4%.